ATE546547T1 - Diagnose der chronischen abstossung - Google Patents

Diagnose der chronischen abstossung

Info

Publication number
ATE546547T1
ATE546547T1 AT03792410T AT03792410T ATE546547T1 AT E546547 T1 ATE546547 T1 AT E546547T1 AT 03792410 T AT03792410 T AT 03792410T AT 03792410 T AT03792410 T AT 03792410T AT E546547 T1 ATE546547 T1 AT E546547T1
Authority
AT
Austria
Prior art keywords
transplanted subject
chronic rejection
diagnosis
transplanted
subject
Prior art date
Application number
AT03792410T
Other languages
English (en)
Inventor
Andreas Krause
Detlef Niese
Friedrich Raulf
Andreas Scherer
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE546547T1 publication Critical patent/ATE546547T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT03792410T 2002-08-22 2003-08-21 Diagnose der chronischen abstossung ATE546547T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40522502P 2002-08-22 2002-08-22
PCT/EP2003/009292 WO2004018710A2 (en) 2002-08-22 2003-08-21 Diagnosis of chronic rejection

Publications (1)

Publication Number Publication Date
ATE546547T1 true ATE546547T1 (de) 2012-03-15

Family

ID=31946831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792410T ATE546547T1 (de) 2002-08-22 2003-08-21 Diagnose der chronischen abstossung

Country Status (7)

Country Link
US (1) US20060099591A1 (de)
EP (1) EP1532278B1 (de)
JP (1) JP2005536212A (de)
AT (1) ATE546547T1 (de)
AU (1) AU2003258648A1 (de)
ES (1) ES2380929T3 (de)
WO (1) WO2004018710A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111210A1 (en) * 2003-12-03 2007-05-17 Marc Bigaud Biomarkers for graft rejection
JP2006014722A (ja) * 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
GB0605217D0 (en) * 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) * 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
GB0607943D0 (en) 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
CA2650507A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
EP2049713A4 (de) * 2006-07-21 2010-06-16 Univ Alberta Gewebeabstossung
EP2031073A1 (de) * 2007-08-31 2009-03-04 TC LAND Expression Diagnose von Immuntransplantatstoleranz mittels TMTC3-Genexpressionsebenen
US10961580B2 (en) 2014-12-19 2021-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting graft alterations
US11855971B2 (en) * 2018-01-11 2023-12-26 Visa International Service Association Offline authorization of interactions and controlled tasks

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883082A (en) * 1990-08-14 1999-03-16 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
JP3236295B2 (ja) 1991-09-24 2001-12-10 ケイヘーネ・エヌ・ベー 選択的な制限断片増幅：一般的なｄｎａフィンガプリント法
US6187534B1 (en) * 1997-09-24 2001-02-13 Cornell Research Foundation, Inc. Methods of evaluating transplant rejection

Also Published As

Publication number Publication date
WO2004018710A3 (en) 2004-09-23
EP1532278A2 (de) 2005-05-25
US20060099591A1 (en) 2006-05-11
ES2380929T3 (es) 2012-05-21
EP1532278B1 (de) 2012-02-22
JP2005536212A (ja) 2005-12-02
AU2003258648A1 (en) 2004-03-11
WO2004018710A2 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
WO2006027192A3 (en) Biomarkers for acute graft rejection
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2005054503A3 (en) Biomarkers for graft rejection
Rembacken et al. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE)
WO2005020784A3 (en) Surrogate cell gene expression signatures for evaluating the physical state of a subject
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE546547T1 (de) Diagnose der chronischen abstossung
WO2008063479A3 (en) Pancreatic cancer biomarkers
WO2007053785A3 (en) Method for early detection of various cancers and gastrointestinal disease and monitoring of transplanted organs.
EP2924440A3 (de) Mit arteriovaskulären ereignissen assoziierte marker und verfahren zur verwendung davon
NO20072853L (no) Diagnose og prognose av infeksjonssykdommers kliniske fenotype og andre fysiologiske tilstander ved anvendelse av genekspresjon av biomarkorer i vertens blod
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
DK1075277T4 (da) Fremgangsmåder til detektion og inhibering af angiogenese
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2004021008A3 (en) Methods for detecting breast and ovarian cancer
ATE354097T1 (de) Verfahren zur diagnose von leberfibrose.
MD3774897T2 (ro) Metode și sisteme de selectare și tratare a pacienților cu boli inflamatorii
CA2575405A1 (en) Method for diagnosing liver fibrosis
JP6062103B2 (ja) 膵臓疾患判定のための方法
WO2009033282A8 (en) Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects